Company profile
IMMUTEP LTD
NASDAQ:IMMPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EFTILAGIMOD ALFA | phase3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06637865 | phase1 | completed | 2024-07-17 | 2026-08-27 | Immutep S.A.S. | A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers |
| NCT00354861 | phase1 | completed | 2005-05-01 | 2005-11-01 | Immutep S.A.S. | A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321 |
| NCT04252768 | phase1 | withdrawn | 2023-06-01 | 2025-06-01 | Immutep S.A.S. | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel |
| NCT04811027 | phase2 | completed | 2021-08-27 | 2024-03-11 | Immutep S.A.S. | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC |
| NCT03625323 | phase2 | completed | 2019-02-21 | 2022-06-02 | Immutep S.A.S. | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC |
FDA applications (0)
No records yet.